News

The technology is incorporated in the company’s AtherOx product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease. According to the company, the

Under the licensing agreement, Celldex has granted a worldwide fee- and royalty-bearing exclusive license to Vaccine Technologies (VTI) to develop and commercialize Celldex’s CholeraGarde and enterotoxigenic Escherichia coli

Grass Neurotrac III software has received the 510(k) clearance for the intended use of recording the electroencephalogram (EEG) and the computed EEG trends over extended periods of time

The testing performed by Accu-Chem includes analyses of body fluids and tissues for recognized toxic chemicals including chlorinated pesticides, volatile solvents, and polychlorinated biphenyls. These tests, which will

The AZ-104 Phase IIb clinical trial is an outpatient, multi-center, randomized, double-blind, single-dose, placebo-controlled study in approximately 360 patients who have migraines, with or without aura. Approximately three

Abraxis BioScience will be solely dedicated to building its Abraxane franchise on a global basis, advancing an extensive Phase III clinical program, and leveraging its proprietary nab technology

If the extension is approved, 3SBio expects that TPIAO for idiopathic thrombocytopenic purpura (ITP) will be the only treatment of this kind available in China. Launched in 2006,

The financing was led by Sanderling Ventures of San Mateo, California. Additional investors include Mitsui & Co Venture Partners of New York. Axikin’s pipeline includes an advanced preclinical

Gunnar Saelid, CEO of Lytix Biopharma, said: “The company has made significant progress in 2008, initiating full preclinical development activities for two important projects. LTX-109 is a novel